Les immunoglobulines intraveineuses (IVIg) constituent une préparation polyclonale d’IgG isolée et regroupée à partir du plasma sanguin de multiples donneurs. Initialement utilisé comme traitement de remplacement chez les patients souffrant d’immunodéficience primaire ou secondaire, les IVIg sont maintenant largement utilisées dans le traitement de plusieurs conditions auto-immunes, allergiques ou inflammatoires à une dose élevée, dite immunomodulatrice. Différents mécanismes d’action ont été postulés au fil des années pour expliquer l’effet thérapeutique des IVIg dans les maladies auto-immunes et inflammatoires. Entre autre, un nombre grandissant de données issues de modèles expérimentaux chez l’animal et l’humain suggère que les IVIg induisent l’expansion et augmentent l’action suppressive des cellules T régulatrices (Tregs), par un mécanisme qui demeure encore inconnu. Également, les patients atteints de maladies auto-immunes ou inflammatoires présentent souvent un nombre abaissé de Tregs par rapport aux individus sains. Ainsi, une meilleure compréhension des mécanismes par lesquels les IVIg modulent les cellules T régulatrices est requise afin de permettre un usage plus rationnel de ce produit sanguin en tant qu’alternative thérapeutique dans le traitement des maladies auto-immunes et inflammatoires. Par le biais d’un modèle expérimental d’allergie respiratoire induite par un allergène, nous avons démontré que les IVIg diminuaient significativement l’inflammation au niveau des voies aériennes ce, en association avec une différenciation des Tregs à partir des cellules T non régulatrices du tissu pulmonaire. Nous avons également démontré qu’au sein de notre modèle expérimental, l’effet anti-inflammatoire des IVIg était dépendant des cellules dendritiques CD11c+ (CDs) pulmonaires, puisque cet effet pouvait être complètement reproduit par le transfert adoptif de CDs provenant de souris préalablement traitées par les IVIg. À cet effet, il est déjà établi que les IVIg peuvent moduler l’activation et les propriétés des CDs pour favoriser la tolérance immunitaire et que ces cellules seraient cruciales pour l’induction périphérique des Tregs. C’est pourquoi, nous avons cherché à mieux comprendre comment les IVIg exercent leur effet sur ces cellules. Pour la première fois, nous avons démontré que la fraction d’IgG riche en acide sialique (SA-IVIg) (constituant 2-5% de l’ensemble des IgG des donneurs) interagit avec un récepteur dendritique inhibiteur de type lectine C (DCIR) et active une cascade de signalement intracellulaire initiée par la phosphorylation du motif ITIM qui est responsable des changements observés en faveur de la tolérance immunitaire auprès des cellules dendritiques et des Tregs. L’activité anti-inflammatoire de la composante SA-IVIg a déjà été décrite dans des études antérieures, mais encore une fois le mécanisme par lequel ce traitement modifie la fonction des CDs n’a pas été établi. Nous avons finalement démontré que le récepteur DCIR facilite l’internalisation des molécules d’IgG liées au récepteur et que cette étape est cruciale pour permettre l’induction périphérique des Tregs. En tant que produit sanguin, les IVIg constitue un traitement précieux qui existe en quantité limitée. La caractérisation des mécanismes d’action des IVIg permettra une meilleure utilisation de ce traitement dans un vaste éventail de pathologies auto-immunes et inflammatoires. / Intravenous immunoglobulin (IVIg) is a therapeutic preparation of normal human polyclonal IgG derived from pooled plasma from a large number of healthy donors. Initially used as replacement therapy for patients with primary and secondary immune deficiencies, IVIg is now also widely used for the treatment of a variety of autoimmune, allergic and systemic inflammatory disorders, at high immunomodulatory doses. The beneficial effect of IVIg in autoimmune and inflammatory diseases has been attributed to different mechanisms. Increasing evidence shows that IVIg induces expansion and enhances the suppressive function of regulatory T cells (Tregs) in different experimental animal models and human subjects, through an unknown mechanism. Human inflammatory and autoimmune diseases are known to be associated with Treg deficiency. Therefore, a more precise understanding of the mechanisms by which IVIg modulate Treg populations seems to be needed for more rational use of this compound as an alternative therapy in context of various inflammatory and autoimmune disorders. Using a robust antigen-driven model of allergic airway disease, we have demonstrated that IVIg markedly attenuates airway inflammation and this effect is associated with the induction of Tregs from non-regulatory T cells in pulmonary tissues. We have also demonstrated that the antiinflammatory actions of IVIg, in our model are dependent on a population of pulmonary CD11c+ dendritic cells (DCs), as the action of IVIg could be completely replicated by adoptive transfer of CD11c+ DCs from IVIg-treated mice. we have shown that tolerogenic DCs involve in the peripheral induction of Tregs. Given the requirement of DCs in the induction of Tregs, we explored the mechanism by which IVIg interacts and modulate these cells and for the first time demonstrated that the purified sialylated fraction of human IgG (SA-IVIg) (that consists 2-5% of whole IgG) interacts with an inhibitory C-type lectin receptor on dendritic (DCIR) and this interaction triggers an ITIM intracellular signaling cascade. This subsequently results in rendering tolerogenic activities to DCs and peripheral induction of Tregs. The anti-inflammatory activity of SA-IVIg has been shown in previous studies, but the mechanism by which it modulates DCs functions is not well understood. We also demonstrated that DCIR facilitates the internalization of IgG molecules into DC and this internalization appears to be a crucial step for induction of Tregs. IVIg is a costly therapeutic compound. Characterization of the mechanism of action of IVIg can lead to a better application of this plasma based therapy in a wide range of autoimmune and inflammatory diseases.

A asma é uma doença heterogênea caracterizada por um processo inflamatório crônico das vias aéreas inferiores que está associado ao desenvolvimento da hiperresponsividade brônquica e remodelamento da via aérea. Atualmente, a asma é considerada uma síndrome, ou ao menos uma doença com diversos fenótipos. Tradicionalmente, dois fenótipos são bem definidos pela clínica e exames subsidiários: asma alérgica e asma não alérgica. Eles são diferentes quanto á idade de início, apresentação clínica, história pessoal e familiar de atopia e resposta ao tratamento. Ao contrário da asma alérgica, cuja fisiopatologia está bem caracterizada, a etiologia e mecanismos envolvidos na asma não alérgica não estão bem elucidados. Algumas possibilidades incluem alergia desencadeada por antígenos desconhecidos (fungos), infecção persistente (Chlamydia trachomatis, Mycoplasma sp) e auto-imunidade. Estudos têm descrito em diferentes populações associações entre a asma e alelos/antígenos HLA classe I e II, mas os resultados têm sido inconclusivos. O objetivo deste estudo foi identificar possíveis associações do antígeno leucocitário humano (HLA) classe I (A, B, C) e II (DR, DQ, DP) em pacientes brasileiros com asma alérgica e não alérgica. Um total de 109 pacientes com o diagnóstico de asma (56 com asma alérgica e 53 com asma não alérgica) que estavam em acompanhamento no Serviço de Imunologia Clínica e Alergia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, e 297 controles (doadores falecidos de órgãos sólidos) tiveram seu sistema HLA classe I (A, B e C) e II (DR, DQ e DP) tipificado. Os pacientes também realizaram espirometria e coletaram sangue para a quantificação da imunoglobulina E (IgE) sérica total e nível sérico de eosinófilos. Além disso, foram avaliados quanto à IgE específica para aeroalergenos através do teste cutâneo de puntura e a pesquisa da IgE sérica específica (ImmunoCAP). O grupo com asma alérgica foi constituído por pacientes que apresentavam resultado positivo para a pesquisa da IgE específica em ambos teste cutâneo de puntura e na investigação in vitro. E o grupo com asma não alérgica apresentava resultados negativos nos dois testes. A comparação do HLA classe I nos grupos estudados identificou frequência significativamente maior do HLA-B*42 e HLA-C*17 no grupo com asma alérgica, enquanto o HLA-B*48 estava estatisticamente associado com o fenótipo não alérgico. Na análise do HLA classe II, o HLA-DPA1*03 e HLA-DPB1*105 apresentou associação com os pacientes com asma alérgica. Concluindo, o estudo observou diferentes associações dos alelos HLA classe I e II com asma alérgica e não alérgica na população brasileira, a qual é caracterizada pela diversidade de origens e miscigenação. Porém, a predisposição genética para asma é poligênica e novos estudos em grandes populações são necessários para confirmar a associação do HLA como fator protetor ou causador da doença / Asthma is a heterogeneous chronic inflammatory disease of lower airways associated with the development of bronchial hyperresponsiveness and airway remodeling. Currently, asthma is regarded as a syndrome or at least a disease with several phenotypes.Traditionally, two phenotypes of asthma have been defined according to clinical and laboratory features: allergic and non-allergic asthma. Each of them has distint age of onset, clinical presentation, personal and family history of allergy and response to therapy. In contrast to allergic asthma, which pathophysiology is well characterized, the etiology and mechanisms involved in non-allergic asthma remain unclear. Some possibilities include allergy triggered by unknow antigens (fungi), persistent infection (Chlamydia trachomatis, Mycoplasma sp) and autoimmunity. Studies have reported associations between asthma and HLA class I and II alleles/antigens in different populations, but the results have been inconclusive. The objective of this study was to identify possible associations of the human leukocyte antigens (HLA) class I (A, B and C) and II (DR, DQ and DP) in Brazilian patients with allergic and non-allergic asthma. A total of 109 patients with asthma (56 with allergic asthma and 53 with non-allergic asthma), who were being followed at the Service of Clinical Immunology and Allergy of the Hospital das Clínicas of the University of São Paulo Medical School, and 297 controls (deceased solid organ donors) had their HLA class I (A,B and C) and II (DR, DQ and DP) typing. Patients performed spirometry and had their blood drawn to measure total serum immunoglobulin E (IgE) levels and eosinophil count. Furthermore, they were assessed for specific IgE to aeroallergens with skin prick test and serum tests (ImmunoCAP). The allergic asthma group was composed of patient presenting positive results for specific IgE in both skin prick test and in vitro assay. And the non-allergic asthma group had negative results in both tests. There were significantly higher frequencies of HLA-B*42 and HLA-C*17 in the allergic asthma group, whereas the HLA-B*48 was associated with the non-allergic group. Regarding HLA class II analysis, HLA-DPA1*03 and HLA DPB1*105 were associated with allergic asthma patients. In conclusion, the study identified different associations of HLA class I and II with allergic and non-allergic asthma in the Brazilian population, which is characterized by diversity of origins and miscegenation. However, the genetic predisposition of asthma is polygenic and new studies on large populations are needed to confirm the role of HLA as a protective or predisposing factor of disease

INTRODUÇÃO: A endomiocardiofibrose (EMF) é uma doença típica de países tropicais, na qual ocorre a deposição de uma capa fibrosa na região endomiocárdica com graves consequências clínicas. A patogenia da EMF ainda não foi elucidada, mas uma das principais hipóteses etiológicas sugere que a EMF seja consequência de um processo inflamatório crônico com envolvimento de respostas imunes Th2 pós-infestação helmíntica, mediada por eosinófilos nas fases iniciais da doença. Neste estudo avaliamos o perfil da resposta imune e inflamatória, assim como o perfil de proteínas expressas no endomiocárdio afetado, para compreender melhor os mecanismos envolvidos na patogênese da EMF. MÉTODOS: Foram coletadas amostras de plasma e soro de pacientes com diagnóstico de EMF e de indivíduos saudáveis, para dosagens de 6 citocinas plasmáticas do perfil Th1/Th2, Proteína C Reativa ultrassensível (PCRus), IgE total e IgE específico contra aero-alérgenos prevalentes e alérgenos de helmintos. A análise proteômica do endomiocárdio afetado de quatro pacientes com EMF submetidos à ressecção cirúrgica da fibrose, levou à identificação por espectrometria de massas, de proteínas separadas previamente por gel 1D e 2D. Análises in silico de vias funcionais e redes ligando as proteínas identificadas também foram realizadas. Eosinofilia em sangue periférico, assim como dados clínicos e ecocardiográficos, foram avaliados retrospectivamente. RESULTADOS: Foram selecionados 27 pacientes em estágio avançado da EMF, portadores de disfunção diastólica e/ou valvar. Todas as amostras de plasma analisadas apresentaram níveis detectáveis de pelo menos uma das citocinas avaliadas. As citocinas IL-6, TNF-?, IL-10 e IL-4 foram detectadas em pelo menos 74% das amostras, sendo que os níveis de IL-6, TNF-? e IL-10 se apresentaram significantemente elevados em comparação com os detectados nos indivíduos saudáveis. Foi observada correlação positiva entre os níveis de todas as citocinas avaliadas. Apenas 33% dos pacientes apresentaram algum episódio isolado de eosinofilia periférica ao longo do tempo, sendo que 11% apresentaram hipereosinofilia. Os níveis de IgE total foram semelhantes aos observados na população controle. A análise proteômica permitiu identificar 140 proteínas distintas no tecido endomiocárdico, das quais 18 eram provenientes da matriz extracelular. As análises in silico indicaram IL-6 e TNF-? como dois dos principais indutores da expressão das proteínas identificadas e a principal via canônica envolvida nas proteínas identificadas foi a: \"Resposta de Fase Aguda\". Coincidentemente, os níveis de PCRus encontraram-se significativamente aumentados nos portadores de EMF. CONCLUSÕES: Elevados níveis de citocinas pró e anti-inflamatórias e de PCRus sugerem a presença de perfil inflamatório misto (Th1/Th2) nas fases avançadas da patogênese da EMF. A pouca expressão da eosinofilia descarta sua participação ativa na patogênese da fase avançada da doença, mas não é possível excluir sua participação nas fases iniciais. Nossos dados permitem levantar a hipótese que os níveis elevados de citocinas inflamatórias modulem a expressão de proteínas- incluindo as de fase aguda- no tecido endomiocárdico de pacientes portadores de EMF / INTRODUCTION: Endomyocardial fibrosis (EMF) is a typical disease in tropical countries, characterized by the fibrous deposition in the endomyocardium, with severe clinical manifestations. EMF pathogenesis is still unclear, but one of the major hypothesis suggests that EMF could be a consequence of a chronic inflammatory process with possible involvement of a Th2 immune responses after helminthiasis, mediated by eosinophils, which could contribute to pathogenesis in the early stages of the disease. In this study, we evaluated the inflammatory response profile and the protein expression profile of the affected endomyocardium, to understand the mechanisms involved in this pathogenesis. METHODS: Plasma and serum samples were collected from the 27 patients diagnosed with advanced stage EMFand from healthy controls, to mensured plasma levels of 6 cytokines belonging to the Th1/Th2 cytokine profiles, ultrasensitive C Reactive Protein (CRP), total and allergen-specific serum IgE against prevalent and helminthic allergens. Proteomic analysis of tissue samples obtained from 4 EMF patients submitted to surgical resection of affected endomyocardial tissue allowed the identification of proteins by mass spectrometry, after separation by 1D and 2D electroforesis. In silico analysis of functional pathways and networks connecting the proteins identified in the EMF cardiac tissue was also performed. Blood peripheral eosinophilia, clinical and echocardiography data were evaluated retrospectively. RESULTS: All EMF patients displayed detectable plasma levels of at least one of the cytokines tested. We found that TNF-?, IL-6, IL-4 and IL-10 were each detected in at least 74% of tested sera, and plasma levels of IL10, IL6 and TNF-? were significantly higher than controls. Plasma levels of such cytokines positively correlated with each other. Only 33% of the patients presented any episode of blood eosinophilia along time, and 11% of these patients presented hypereosinophilia. Total IgE levels were similar to those from healthy subjects. Proteomic analysis allowed the identification of 140 distinct proteins from the resected endomiocardium of the EMF patients, 18 of which belonging to the extracellular matrix. In silico analysis indicated IL-6 and TNF-? as two of the major gene expression inducers of the identified proteins in our analysis, and the Acute Phase Response was identified as the major canonical pathway involved with the identified set of proteins. Similarly, CRP levels were significantly increased in the EMF patients. CONCLUSIONS: Increased levels of an inflammatory/anti-inflammatory circulating cytokines (Th1/Th2), along with increased CRP levels, suggested the presence of a mixed inflammatory profile in EMF advanced stage. The number of EMF patients with blood eosinophilia does not support the active participation of eosinophils in pathogenesis of advanced EMF. However, it is not possible to exclude the participation in the pathogenesis early stages. Our data support the hypothesis that the increased levels of inflammatory cytokines modulate protein expression -including proteins of the acute phase response - in the endomyocardial tissue of EMF patients

Os efeitos protetores da imunidade humoral são medidas por uma família de glicoproteínas chamadas anticorpos ou imunoglobulinas. As preparações de imunoglobulina G (IgG) utilizadas em nosso país são importantes. No Brasil, a primeira preparação de IgG foi obtida na Fundação Pró-Sangue Hemocentro de São Paulo em 1993. O presente estudo avaliou preparações de IgG obtidas de misturas de plasma humano de variadas procedências, inclusive a preparação obtida no Brasil. Foram avaliados os seguintes parâmetros: concentração protéica, distribuição das subclasses da IgG, atividade de anticorpos específicos e segurança quanto a agentes patogênicos transmissíveis pelo sangue. Em algumas preparações, a concentração protéica de IgG e a distribuição das suas subclasses estavam fora das especificações. As preparações apresentaram atividade de anticorpos específicos contra os vírus das hepatites A e B, do herpes simples, da rubéola, citomegalovírus; contra a bactéria Streptococcus pyogenes β-hemolítico do grupo A e contra o parasita Toxoplasma gondii. A qualidade de matéria-prima utilizada em algumas das preparações de IgG não foi adequada em função de reações positivas para anticorpos contra alguns agentes infecciosos, tais como HTLV I/II, HAV, HBV, HCV e Treponema pallidum. Esse estudo também mostrou a necessidade de se implantar urgente um programa abrangente para avalição das preparações de IgG a serem consumidas pela população brasileira. / A family of glicoproteins, which are called antibodies or immunoglobulins (IgG), mediates the protective effects of humoral immunity. In Brazil, the IgG for intravenous use are imported from other countries. The first Brazilian immunoglobulin G for therapheutic use was obtained from human plasma at the Fundação Pró-Sangue Hemocentro de São Paulo. The present study was carried out to evaluate different preparations of IgG, human plasmad-derived, include the preparation from Brazil. The protein concentration, IgG subclass distribution, specific antibody activities and safety regarding the main blood transmitted infectious diseases were analyzed. In some preparations, IgG protein concentration and subclass distribution were different from their specifications. Some preparations showed specific antibody activity against the following antigens: A and B hepatitis virus, rubella, herpes simplex virus, citomegalovirus, measles virus, Streptococcus pyogenes β-hemolytic group A and Toxoplasma gondii. The presence of antibodies against antigens such as HTLV I/II, HAV, HBV, HCV and Treponema pallidum has compromissed the quality guaranty of the material-source (plasma) used in some preparations. This study has also showed that a complete and effective program for the quality evaluation of IgG preparations used in Brazil is needed and should be urgently established

A Imunodeficiência Comum Variável (ICV) e a Deficiência Seletiva de Imunoglobulina A (DIgA) são as imunodeficiências primárias humorais de maior freqüência na população mundial. Ambas as doenças são caracterizadas pela ausência ou redução significativa de imunoglobulinas no soro. Embora diversas anormalidades imunológicas tenham sido associadas a estas doenças, nenhuma hipótese unificadora a respeito das bases moleculares das mesmas foi proposta até o presente momento, sendo que o único defeito comum a todos os pacientes é a falha na diferenciação de células B em plasmócitos e conseqüente secreção de anticorpos. Devido à alta incidência de auto-imunidade e alergia em pacientes com ICV e DIgA, no presente trabalho, visamos analisar por citometria de fluxo a população de linfócitos CD4+ com potencial regulador nesses pacientes, para avaliar se possíveis defeitos quantitativos ou funcionais nesta população reguladora poderiam explicar a alta incidência de doenças auto-imunes ou alérgicas associadas a estas imunodeficiências. / Common Variable Immunodeficiency (CVID) and Selective Immunoglobulin A deficiency (IgAD) are the humoral primary immunodeficiencies with the highest incidence in the population. Both diseases are characterized by the absence or significant reduction of serum immunoglobulins. Although several immunological abnormalities have been associated with these diseases, no unifying hypothesis regarding the molecular basis of CVID and IgAD have been proposed to date, and the only defect common to all patients is the failure in differentiation of B cells into plasma cells and consequent secretion of antibodies. Due to the high incidence of autoimmunity and allergy in patients with CVID and IgAD, in the present work we analyzed by flow cytometry the population of CD4+ lymphocytes with regulatory potential in these patients to assess whether possible quantitative or functional defects in this regulatory population could explain the high incidence of autoimmune diseases or allergic reactions associated with these immunodeficiencies.

A via de Reparo por Excisão de Nucleotídeos (NER) é responsável pelo reparo das lesões causadas pela luz ultravioleta (UV) e de outras lesões capazes de distorcer a dupla hélice, bloqueando a replicação e a transcrição. Os pacientes que apresentam as síndromes recessivas raras Xeroderma Pigmentosum (XP), tricotiodistrofia (TTD) e síndrome de Cockayne (CS) possuem mutações em algum dos 11 genes relacionados ao NER e à transcrição basal. Mutações na proteína XPD levam ao surgimento de diferentes fenótipos: XP, TTD, XP/CS ou COFS (Cerebro-Oculo-Facio-Skeletal Syndrome), uma forma rara de CS. Os pacientes XP apresentam alta incidência de câncer de pele, o que não ocorre com os pacientes TTD e CS, além de poderem apresentar perda neuronal progressiva, enquanto todos os CS e TTD apresentam uma diminuição na mielinização do cérebro. As neuropatologias são provavelmente associadas a problemas no reparo de danos endógenos no DNA das células nervosas. Diversos trabalhos mostraram o envolvimento do NER no reparo desses danos, os quais pensava-se serem reparados apenas por outro mecanismo, o Reparo por Excisão de Base. Neste trabalho mostramos que fibroblastos de pacientes XP-D, XP-D/CS e TTD, portadores de mutações em XPD, são sensíveis ao estresse oxidativo induzido pelo tratamento com azul de metileno fotoativado, apresentando bloqueio prolongado no ciclo celular e permanência da sinalização de danos ao DNA. A complementação das diferentes linhagens com o gene XPD/ERCC2 foi capaz de restaurar a sobrevivência celular. Foram detectadas diferenças importantes na capacidade de reparo/retomada da transcrição após danos gerados por estresse oxidativo em DNA plasmidial, além da ativação de vias diferentes de morte celular: fibroblastos XP-D apresentam maior capacidade de reparo e apresentam morte por apoptose após estresse oxidativo, enquanto os fibroblastos XP-D/CS e TTD apresentam menor capacidade de reparo ativação de mais de uma via de morte celular (apoptose e necrose), diferenças que podem estar ligadas ao fenótipo dos pacientes. Mutações no gene codificante para a DNA polimerase n, POLH, estão associadas à forma variante de XP (XP-V). Pol n é uma polimerase especializada na síntese translesão (TLS) de fotoprodutos, além de estar implicada na TLS de outros tipos de lesões como bases oxidadas, e em vias não relacionadas à TLS como a hipermutação somática e à replicação de regiões de DNA com arquiteturas não-canônicas. Neste trabalho mostramos que os fibroblastos de pacientes XP-V apresentam sensibilidade ao estresse oxidativo. Mostramos uma indução da proteína pol n em fibroblastos primários após danos genotóxicos, associada ao aumento da capacidade de lidar com a parada na forquilha de replicação, possibilitando a continuidade da replicação do DNA e ao aumento da sobrevivência celular. Mostramos uma diferença na estabilidade genômica nos genes das imunoglobulinas dos pacientes XP-V idosos em comparação com os pacientes jovens e controles de idade pareada, mostrando que a ausência dessa polimerase pode estar ligada ao aumento da instabilidade genômica nesses genes / The Nucleotide Excision Repair (NER) pathway is responsible for the repair of UV photoproducts and other bulky lesions that block both replication and transcription. Patients with the rare recessive disorders Xeroderma Pigmentosum (XP), trichothiodystrophy (TTD) and Cockayne Syndrome (CS) carry mutations in one of the 11 NER genes, linked to repair and basal transcription. Mutations in XPD lead to different phenotypes: XP, TTD, XP/CS or COFS (Cerebro-Oculo-Facio-Skeletal Syndrome), a rare form of CS. XP patients have high incidence of skin cancer, which does not occur in TTD or CS patients, although ther may present neurodegeneration, while all CS and TTD patients have neurodevelopmental symptoms linked to dysmielynation. The pathology of these neurological diseases is probably associated with deficient repair of DNA lesions in nervous cells, generated by endogenous processes. Many groups including ours have demonstrated the involvement of NER in the repair of these lesions, previously thought to be exclusively repaired by Base Excision Repair. In this work we show high sensitivity of both primary and transformed XP-D, XP-D/CS and TTD human fibroblasts in response to oxidative stress generated by photoactivated methylene blue, with prolonged cell cycle arrest and DNA damage signaling. The complementation of the three different cell lines with the XPD/ERCC2 gene was able to restore cell survival. We detected important differences in repair capacity/transcription resumption after damage generated by oxidative stress in plasmid DNA, besides the activation of different cell death pathways: XP-D cells have higher repair capacity and die by apoptosis, while XP-D/CS and TTD cells have little repair capacity and activate more than one death pathway (apoptosis and necrosis). We believe these differences can be related to the patients\' phenotypes. Mutations in DNA polymerase n coding gene, POLH, are associated with the variant form of XP (XP-V). Pol n is a translesion synthesis (TLS) polymerase specialized in the TLS past CPD photoproducts, besides other lesions like oxidized bases, and in other processes like somatic hypermutation and DNA replication in structured regions. In this work we show XP-V human fibroblasts are sensitive to oxidative stress. We detected an induction of pol n after genotoxic stress in primary cells, associated with increased ability to deal with the stalled replication fork, and consequently to DNA replication restart and cell survival. In addition, we detected a difference in genomic stability in immunoglobulin genes in aged XP-V patients in comparison to both young patients and age-matched controls, showing the absence of this polymerase may be linked to increased genomic instability in these genes

Dans le but de générer une souris transgénique produisant des anticorps humains, les trois loci humains (HC, LCκ et LCλ) ont été reconstitués sous forme de YAC circulaires. Puis, pour simplifier la manipulation des gènes codant pour la chaîne lourde, quatre vecteurs plasmidiques qui résument l’information génétique contenue dans le locus humain de la chaîne lourde ont été réalisés. La construction HC Minilocus (78 kbp) est donc composée des 13 segments V sélectionnés, de la région D-J synthétisée et des gènes codant pour les parties constantes de type μ, ɣ3 et ɣ1. Trois autres constructions (~22 kbp) ont été dérivées des étapes intermédiaires de clonage. Elles sont basées sur 7 segments V et la région D-J synthétisée. Le HC Microlocus Classic (22 kb) a été obtenu après clonage du gène codant pour la partie constante ɣ1 en 3’ des éléments V, D et J précédemment cités; cette construction code pour des chaînes lourdes d’IgG1 (ɣ1 HC). De la même façon, le HC Microlocus Light (21.5 kb) contient le gène codant pour ɣ1 CH1-, cette construction code donc pour des chaînes lourdes IgG sans domaine CH1 (ɣ1 HC CH1-). Les chaînes lourdes de ce type sont exprimées sans être associées à des chaînes légères, à l’image de ce qui est observé chez les camélidés (Heavy Chain only antibodies). Enfin le HC Microlocus Light shRNA (22 kbp) est une construction basée sur le Microlocus Light à laquelle a été ajoutée une séquence codant pour quatre shRNA (small hairpin RNA) visant à réprimer l’expression d’IgM murin. Ce locus est destiné à être injecté dans des souris natives (wilde type, WT). La fonctionnalité de ces quatre vecteurs a été évaluée par transfection dans la lignée cellulaire 300-19, des lymphocytes pro B d’origine murine pouvant progresser du stade pro B au stade de cellule B mature, lorsqu’elles sont maintenues en culture. Pour les quatre constructions, plusieurs réarrangements DJ et VDJ ont été identifiés, montrant une grande diversité combinatoire et jonctionelle. Par cytométrie en flux (FACS), des chaînes lourdes humaines ont été identifiées dans le cytoplasme et à la surface des cellules transfectées avec les trois constructions intermédiaires. Les cellules exprimant des chaînes lourdes en surface ont été enrichies par FACS. Par la suite, en utilisant des méthodes immuno-enzymatiques (ELISA et ELISPOT), il a été prouvé que les chaines lourdes d’anticorps humains étaient secrétées dans le milieu extracellulaire. La transgénèse avec les constructions HC Microlocus Light et HC Microlocus Light shRNA s’est révélée efficace puisque nous avons obtenu plusieurs animaux transgéniques. Aucune cellule B n’a été détectée dans les souris HC Microlocus Light (background HC KO); alors que cette même construction associée à un shRNA (HC Microlocus Light shRNA) dans une souris transgénique au système immunitaire humoral intact, montre l’expression de chaînes lourdes d’anticorps humains dans le cytoplasme et à la surface des cellules B. La chaine lourde humaine est exprimée en parallèle des immunoglobulines endogènes à la surface des cellules pre-B, ainsi que dans les cellules B immatures et matures. / In order to generate a transgenic mouse producing human antibodies, three human loci (HC, LCκ et LCλ) were reconstituted in the form of circular YAC. Then, to simplify the manipulation of genes encoding the heavy chain, four vectors summarizing the genetic information contained in the human heavy chain locus were designed and cloned. The HC Minilocus (78 kbp) is composed of 13 V segments, a synthetic DJ cluster and the genes encoding the constant parts Cμ, Cɣ3 and Cɣ1. Three other constructions (~22 kbp) were derived from the intermediate cloning steps. They are based on 7 V segments and a DJ region synthesized. The HC Microlocus Classic (22 kbp) was obtained after cloning of the gene encoding the constant part ɣ1 in 3' of the V , D and J elements mentioned above; this construct encodes the heavy chain of IgG1 (ɣ1 HC). The HC Microlocus Light (21.5 kb) contains the gene encoding ɣ1 CH1-, therefore, this construction encodes IgG1 HC without CH1 domain (ɣ1HC CH1-). Such HC are expressed without being associated with light chain (Heavy Chain only antibodies). Finally, the HC Microlocus Light shRNA (22 kb) is based on the HC Microlocus Light to which was added a sequence encoding four shRNA (small hairpin RNA) to repress the murine IgM expression. This locus is designed to be injected into wild type mouse. The functionality of the four reduced human HC constructs was assessed in mouse cells. The 300-19 cell line was used because is a pro-B cell line able to rearrange endogenous or transgenic Ig genes and to express the rearranged genes as Ig proteins. 300-19 cells were transduced with the four reduced human HC constructs and the expression of the transgenic Ig genes was investigated in detail. Indeed, DJ and VDJ rearrangement, recombinatory diversity, junctional diversity, transcription, mRNA maturation, alternative splicing, Ig surface expression and secretion were assessed. The data demonstrated that these constructs undergo editing and processing in murine cells and give rise to a large diversity of human heavy chains. The HC Microlocus Light was injected in HC knock out mouse oocytes and the HC Microlocus Light shRNA (which is exactly identical to the Microlocus Light concerning the antibody gene part) in wild type mouse oocytes. Injection in wild type mice led to human γ1 HC expression, whereas injections in HC KO mice did not show any B cell population reconstitution and consequently no human HC γ1 expression. Transgenic human ɣ1 HC and endogenous mouse IgM are co-expressed at the surface of progenitor-, immature- and mature B cells.

We performed a retrospective study in 185 patients with myelogenous leukemias who had received hematopoietic cells from unrelated donors. The aim of this study was to answer the question wether the benefit of KIR ligand incompatibility seen in haploidentical tranplantations can also be seen using unrelated donors. We could not detect a significant difference in survival between patients with a KIR ligand incompatibility and those with either fully matched or partially mismatched unrelated donors in this patient cohort. / In der Therapie von Leukämien ist die Knochenmark- bzw. Stammzelltransplantation eine tragende Säule. Für den Transplantationserfolg ist eine Übereinstimmung der Haupthistokompatibilitätsantige (HLA-Antigene der Klassen I und II) zwischen Spender und Empfänger von zentraler Bedeutung. Diese Notwendigkeit ergibt sich aus der sogenannten MHC-Restriktion in der T-Zellrezeptorerkennung. Ob auch NK-Zellrezeptoren und deren Liganden in der Spenderauswahl berücksichtigt werden sollten, ist bisher unzureichend untersucht. Insbesondere trifft das für die KIR-Rezeptoren zu, die wie die T-Zellrezeptoren ebenfalls HLA-Antigene als Liganden besitzen. Velardi et al. haben 2002 erstmalig gezeigt, daß in der Therapie myeloischer Leukämien die Transplantation von Blutstammzellen verwandter Spender mit KIR-Liganden-Inkompatibilität von klinischem Vorteil ist. Ob KIR-Liganden-Inkompatibilität auch bei Knochenmark-/ Stammzelltransplantationen Unverwandter Bedeutung erlangen könnte, war zu Studienbeginn offen und blieb auch infolge diskrepanter Untersuchungsergebnisse von verschiedenen Arbeitsgruppen im Verlauf der Studie widersprüchlich. Im Rahmen dieser Arbeit wurde diese Fragestellung, die auch Teil einer internationalen Studie war, an 185 Spender-Empfänger-Paaren retrospektiv untersucht. Dabei wurde bei den Paaren einerseits die KIR-Liganden-Kompatibilität auf der Grundlage der HLA-C-Supertypen erschlossen (nach Velardi et al.). Andererseits konnte sie im internationalen Studienprogramm direkt aus dem KIR-Genotyp des Spenders und dem HLA-C-Supertyp des Empfängers ermittelt werden. Die Untersuchungen ergaben folgende Resultate: bei Vorliegen von KIR-Liganden-Inkompatibilität hat die Verwendung von ATG als Bestandteil der GvHD-Prophylaxe keinen Einfluß auf das klinische Ergebnis. Die Vermutungen von Giebel et al. wurden damit nicht gestützt. Die Bestimmung des KIR-Liganden-Status mit Hilfe der Rückschlußmethode allein aus dem HLA-Typ ist unzuverlässig. Für eine exakte Differenzierung ist die gleichzeitige KIR-Genotypisierung erforderlich. KIR-Liganden-Inkompatibilität ist bei unverwandten Knochenmark-/ Stammzelltransplantationen nicht von klinischem Vorteil. Auch ein gezieltes Aussuchen HLA-C-inkompatibler Spender auf der Grundlage einer KIR-Genotypisierung stellt derzeit keine therapeutische Option dar.

Indiana University-Purdue University Indianapolis (IUPUI) / Signal Transducer and Activator of Transcription 3 (STAT3) is known to be related to bone metabolism. Mutation of STAT3 causes a rare disorder in which serum levels of IgE are elevated. This causes various skeletal problems similar to osteoporosis. To examine the effect of STAT3 in the osteoclast, we obtained two osteoclast specific STAT3 knockout mouse models: one using the CTSK promoter to drive Cre recombinase and another using a TRAP promoter. Examination of these mice at 8 weeks of age revealed a decreased trabecular bone volume in CTSK specific STAT3 knockout mice along with a slight decrease in osteoclast number in both CTSK and TRAP specific STAT3 knockout females. We also noticed changes in bone mineral density and bone mechanical strength in females. These data suggest that STAT3 plays a part in the function of the osteoclast.

Safety concerns arising from cytotoxic behavior of nanoparticles (NPs) in complex biological environment remain the main problem limiting NPs application in biomedicine. In this study, we have investigated cytotoxicity of NPs with different composition, shape and size, namely SiO2 NPs (SiNPs, 7-14 nm), superparamagnetic iron oxide NPs (SPIONs, 8 nm) and carboxylated multiwalled carbon nanotubes (CNTCOOHs, diameter: 60-100 nm, length: 1-2 μm). Cytotoxicity was evaluated with newly designed screening assay capable to simultaneously assess activity of cell dehydrogenases, activity of lactate dehydrogenase (LDH) released from cells into environment and number of intact cell nuclei and apoptotic bodies in human umbilical vein endothelial cell (HUVEC) culture growing in the very same well of the 96-well plate. Aforementioned attributes were subsequently utilized to obtain information about cell viability and necrotic and apoptotic aspects of cell death. Results from this "three-in-one" cell death screening (CDS) assay showed that SiNPs and CNTCOOHs evoked pronounced cytotoxic effect demonstrated as decrease of cell viability and development of apoptotic bodies formation. In contrast to this, SPIONs induced only mild cytotoxicity. Moreover, SiNPs impaired cell membrane leading to increased LDH release...